Radius Health Target of Unusually High Options Trading (RDUS)

Radius Health Inc (NASDAQ:RDUS) saw some unusual options trading activity on Monday. Stock investors purchased 1,862 call options on the stock. This is an increase of approximately 1,269% compared to the typical daily volume of 136 call options.

Radius Health stock opened at $20.79 on Wednesday. Radius Health has a fifty-two week low of $12.81 and a fifty-two week high of $31.92. The company has a market cap of $958.57 million, a P/E ratio of -4.26 and a beta of 0.98. The company has a debt-to-equity ratio of 6.75, a quick ratio of 5.04 and a current ratio of 5.16.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32. Radius Health had a negative net margin of 176.84% and a negative return on equity of 233.12%. The business had revenue of $34.42 million for the quarter, compared to analyst estimates of $33.99 million. Analysts expect that Radius Health will post -3.51 EPS for the current fiscal year.

Several research analysts recently weighed in on the stock. HC Wainwright reissued a “hold” rating on shares of Radius Health in a research note on Thursday, May 9th. Cowen reissued a “hold” rating on shares of Radius Health in a research note on Wednesday, May 8th. Zacks Investment Research raised shares of Radius Health from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Monday, May 6th. BidaskClub lowered shares of Radius Health from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Finally, ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $38.00.

In related news, Director Debasish Roychowdhury sold 4,800 shares of Radius Health stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $22.15, for a total transaction of $106,320.00. Following the transaction, the director now owns 5,500 shares of the company’s stock, valued at approximately $121,825. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jessica Hopfield acquired 12,800 shares of Radius Health stock in a transaction that occurred on Tuesday, March 5th. The shares were purchased at an average cost of $19.23 per share, for a total transaction of $246,144.00. Following the purchase, the director now directly owns 12,800 shares in the company, valued at $246,144. The disclosure for this purchase can be found here. 4.00% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in RDUS. MetLife Investment Advisors LLC lifted its stake in Radius Health by 56.4% in the third quarter. MetLife Investment Advisors LLC now owns 27,474 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 9,912 shares in the last quarter. Vanguard Group Inc. lifted its stake in Radius Health by 1.5% in the third quarter. Vanguard Group Inc. now owns 3,571,571 shares of the biopharmaceutical company’s stock valued at $63,574,000 after buying an additional 53,281 shares in the last quarter. Vanguard Group Inc lifted its stake in Radius Health by 1.5% in the third quarter. Vanguard Group Inc now owns 3,571,571 shares of the biopharmaceutical company’s stock valued at $63,574,000 after buying an additional 53,281 shares in the last quarter. Virtu Financial LLC bought a new position in Radius Health in the fourth quarter valued at approximately $205,000. Finally, Bank of Montreal Can lifted its stake in Radius Health by 231.3% in the fourth quarter. Bank of Montreal Can now owns 1,544 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 1,078 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Radius Health Target of Unusually High Options Trading (RDUS)” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/22/radius-health-target-of-unusually-high-options-trading-rdus.html.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Recommended Story: Compound Interest and Why It Matters When Investing

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.